RefillPill.com - Cheap drugs and prescription medication
RefillPill.com Pharma Links Directory logo

RefillPill.com - Online Health Help
Search : Find drug site

Health Help Resources:
Drug Index
Men's Health
Online Drug News
  • For the nation's drug manufacturers, people like Ed Glazier will write much of the future. The Wilmington retiree and his wife, Katherine, are among millions of Medicare recipients who plan to sign up for the federal health insurance program's new prescription drug benefit that starts Jan. 1.
    read more >>
  • DUBLIN, Ireland----Nov. 21, 2005--Research and Markets has announced the addition of Prostate Cancer - A Prostrate Market Waiting for Innovations to their offering
    read more >>
  • The hearing on November 17 will include oral arguments and could result in a summary judgement in the case, which is due to go to trial in the U.S. District Court for the Eastern District of Missouri on February 13, 2006.
    read more >>
  • Business Finance and city news online from Interactive Investor (www.iii.co.uk). Plus financial and currency market news and information 24/7. Stock prices, share prices, currency markets news and business finance headlines. Also news from AFX and Reuters.
    read more >>


Sign up for FREE to the most read Newsletter on cheap drugs! We track all the drug ads out there and help you zero in on the really great deals.

Enter To Claim your Instant Coupon Code...


Enter to get an instant discount on all your pharmacy needs.

Name:  
Email:  
Privacy

Terms


CASODEX

BRAND NAME: Casodex

GENERIC NAME: bicalutamide

DRUG CLASS AND MECHANISM:

Bicalutamide is an oral medication that is used for treating cancer of the prostate. It belongs to a class of drugs called anti-androgens which includes flutamide (Eulexin) and nilutamide (Nilandron). Androgens (an example of which is testosterone) are hormones that are produced and released by the adrenal glands. They are responsible for supporting (stimulating) tissues that primarily are thought of as male, for example, the male prostate gland. Male traits that also are influenced by androgens include facial and body hair and small breasts. Anti-androgens prevent the action of androgens by blocking the receptors for androgens on the cells of tissues, for example, the cells of the prostate gland. In addition to normal prostate cells, androgens also have been shown to stimulate the growth of cancer cells within the prostate. Bicalutamide is thought to prevent the growth of prostate cancer by blocking the effects of androgens on the cancer cells. Bicalutamide was approved by the FDA in 1995.

PRESCRIPTION:

yes

GENERIC AVAILABLE:

no

PREPARATIONS:

Bicalutamide is available as a 50mg tablet.

STORAGE:

Bicalutamide should be stored at room temperature, 15-30°C(59-86°F).

PRESCRIBED FOR:

Bicalutamide is used in combination with another medication, a gonadotrophin hormone releasing factor, to treat advanced prostate cancer.

DOSING:

Bicalutamide should be taken as one 50mg tablet in the morning or the evening at the same time each day. It may be taken with or without food. Once bicalutamide therapy has begun, it should not be interrupted or stopped without consulting a physician.

DRUG INTERACTIONS:

Bicalutamide may interact with warfarin (Coumadin). Therefore, the dose of Coumadin may need to be adjusted.

PREGNANCY:

Bicalutamide can cause harm to a developing fetus; therefore, it should not be administered to pregnant women or women attempting to become pregnant.

NURSING MOTHERS:

It is not known if bicalutamide is excreted in breast milk.

SIDE EFFECTS:

When bicalutamide and a gonadotrophin releasing factor analog are given together, the most common side effect is hot flashes (50% of patients) and facial flushing. Alcohol may worsen this reaction, and so it should be cautiously consumed. Other common side effects of the combination are diarrhea, constipation and overall pain including pain in the back, hips and stomach. Less common side effects are breast enlargement and breast pain, which may be due to the bicalutamide alone.